DNA vaccination

Expert Opinion on Emerging Drugs

Volumn 8, Issue 1, 2003, Pages 27-35

  Ada, Gordon ^a   Ramshaw, Ian ^a  

^a Biology and Environment   (Australia)

Author keywords

Antibody; Cancer; Cytotoxic T lymphocytes; Dendritic cells; Infectious disease; Plasmid DNA; Vaccination; Vaccine

Indexed keywords

BACTERIAL DNA; CD14 ANTIGEN; CD4 ANTIGEN; CD40 ANTIGEN; CD8 ANTIGEN; CHEMOKINE RECEPTOR CCR4; CHEMOKINE RECEPTOR CCR7; DNA VACCINE; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; IMMUNOGLOBULIN G2A; INACTIVATED VACCINE; INTERLEUKIN 12; INTERLEUKIN 4; INTERLEUKIN 6; LIVE VACCINE; T LYMPHOCYTE RECEPTOR; TOXOID;

ANTIBODY RESPONSE; CELL ACTIVATION; CPG ISLAND; CYTOTOXIC T LYMPHOCYTE; DENDRITIC CELL; DRUG EFFICACY; DRUG RESEARCH; DRUG SAFETY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; IMMUNOGENICITY; IMMUNOLOGICAL MEMORY; INFECTION; NONHUMAN; REVIEW; TH1 CELL; VACCINATION; VACCINE PRODUCTION;

ANIMALS; CLINICAL TRIALS; DNA, BACTERIAL; HUMANS; T-LYMPHOCYTES; VACCINES, DNA;

EID: 0038657764     PISSN: 14728214     EISSN: None     Source Type: Journal    
DOI: 10.1517/14728214.8.1.27     Document Type: Review

References (53)

1. WOLFF JA, MALONE RW, WILLIAMS P et al.: Direct gene transfer into mouse muscle in vivo. Science (1990) 247:1465-1468.
2. TANG DC, DE VIT M, JOHNSTON SA: Genetic immunization is a simple method for eliciting an immune response. Nature (1992) 356:152-154. The first report showing that immunisation with a chimeric DNA preparation resulted in an immune response to the foreign protein encoded in the DNA.
3. ULMER JB, DONNELLY JJ, PARKER SE et al.: Heterologous protection against influenza by injection of DNA encoding a viral protein. Science (1993) 259:1745-1749.
4. ROBINSON HL, HUNT LA, WEBSTER RG: Protection against a lethal influenza virus challenge by immunization with a hemagglutinin-expressing plasmid DNA. Vaccine (1993) 11:957-960.
5. BRAMSON JI, WAN Y-H: The efficacy of genetic vaccination is dependent upon the nature of the vector system and antigen. Expert Opin. Biol. Ther. (2002) 2(1):75-85.
6. + T cell responses elicited by a bicistronic HIV-1 DNA vaccine expressing gp120 and GM-CSF. J. Immunol. (2002) 168:562-568.
7. KRIEG AM: CpG motifs in bacterial DNA and their immune effects. Ann. Rev. Immunol. (2002) 20:709-760. A comprehensive review outlining the importance of CpG motifs in bacterial DNA.
8. ROBINSON HL: New hope for an AIDS vaccine. Nat. Rev. Immunol. (2002) 2:239-250.
9. MODLIN RL: A toll for DNA vaccines. Nature (2000) 408:659-660. The finding that bacterial DNA with CpG motifs is recognised by the toll-like receptor 9 (TLR9) on the surface of dendritic cells and thereby facilitates their activation and maturation.
10. SATO K, KAWASAKIH, NAGAYAMA H et al.: Signalling events following chemokine receptor ligation in human dendritic cells at different developmental stages. Int. Immunol. (2001) 13:167-179.
11. LANZAVECCHIA A, SALLUSTO F: Regulation of T cell immunity by dendritic cells. Cell (2001) 106:263-266. Provides a quantitative estimate of the time needed to activate naive versus memory T cells following contact with the antigen- presenting cell.
12. UWIERA RRE, GERDTS V, PONTAROLLA RA et al.: Plasmid DNA induces increased lymphocyte trafficking: a specific role for CpG motifs. Cell Immunol. (2001) 214:155-164.
13. GURUNATHANS, KLINMAN DM, SEDER RA: DNA vaccines: immunology, application and optimization. Ann. Rev. Immunol. (2000) 18:927-974.
14. + T cell responses to dominant and subdominant epitopes and protective immunity to Sendai virus infection by DNA vaccination. J. Immunol. (1998) 160:2425-2432.
15. FU TM, FRIEDMAN A, ULMER JB, LIU MA, DONNELLY JJ: Protective cellular immunity: cytotoxic T lymphocyte responses against dominant and recessive epitopes of influenza virus nucleoprotein induced by DNA immunization. J. Virol. (1997) 71:2715-2721.
16. YOKOYAMA M, ZHANG J, WHITTON JL: DNA immunization confers protection against lethal lymphocytic choriomeningitis virus infection. J. Virol. (1995) 69:2684-2688. A report indicating that bacterial DNA including DNA coding for a foreign protein induces a strong memory response to the foreign proteins.
17. + cytotoxic T cells: implications for vaccine design. Proc. Natl Acad. Sci. USA (1995) 63:375-380.
18. THOMSON SA, ELLIOTT SL, SHERRITT MA et al.: Recombinant polyepitope vaccines for the delivery of multiple CD8 cytotoxic T cell epitopes. J. Immunol. (1996) 157:822-826.
19. HANKE T, SAMUEL RV, BLANCHARD TJ et al.: Effective induction of simian immunodeficiency virus-specific cytotoxic T lymphocytes in macaques by using a multiepitope gene and DNA prime-modified vaccinia virus Ankara boost vaccination regimen. J. Virol. (1999) 73(9):7524-7532.
20. RAMSAY AJ, KENT SJ, STRUGNELL RA, SUHRBIER A, THOMSON SA, RAMSHAW IA: Genetic vaccination strategies for enhanced cellular, humoral and mucosal immunity. Immunol. Rev. (1999) 171:27-44. A review describing the benefits of a DNA priming and a different booster immunising regime in inducing a much enhanced immune response.
21. SLIFKA MK, ANTIA R, WHITMIRE JK, AHMED R: Humoral immunity due to long-lived plasma cells. Immunity (1998) 8:363-372.
22. MULLBACHER A: The long-term maintenance of cytotoxic T cell memory does not require persistence of antigen. J. Exp. Med (1994) 179:317-321.
23. HEDLEY M, CURLEY J, URBAN R. Microspheres containing plasmid-encoded antigen elicits cytotoxic T cell responses. Nat. Med. (1998) 4:365-368.
24. O'HAGAN D, SINGH M, UGOZZULI M et al.: Induction of a potent immune response by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccine. J. Virol. (2001) 75:9037-9043.
25. ALEXANDER-MILLER MA, LEGGATT GR, BERZOFSKY JA: Selective expansion of high- or low-avidity cytotoxic T lymphocytes and efficacy for adoptive immunotherapy. Proc. Natl Acad. Sci USA (1996) 93:4102-4107.
26. YEE C, SAVAGE PA, LEE PP, DAVIS MM, GREENBERG PD: Isolation of high avidity melanoma-reactive CTL from heterogeneous populations using peptide-MHC tetramers. J. Immunol. (1999) 162:2227-2234.
27. + cytotoxic T lymphocyte population. Int. Immunol. (2002) 14:31-37.
28. RAMSHAW IA, RAMSAY AJ: The prime-boost strategy: exciting prospects for improved vaccination. Immunol. Today (2000) 21:163-165.
29. LEONG KH, RAMSAY AJ, MORIN MJ et al.: Generation of enhanced immune responses by consecutive immunization with DNA and recombinant fowlpox virus. In: Vaccines 95. Brown F, Chanock R, Ginsberg H, Norrby E (Eds), Cold Springs Harbor Laboratory Press (1995):327-331.
30. +T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara. Nat. Med (1998) 4:397-402.
31. ALLEN TM, VOGEL TU, FULLER DH et al.: Induction of AIDS virus-specific CTL activity in fresh, unstimulated peripheral blood lymphocytes from rhesus macaques vaccinated with a DNA prime/modified vaccinia virus Ankara boost regimen. J. Immunol. (2000) 164:4968-4978. The first detailed report indicating that in contrast to ASCs formed early in an immune response which have a short half-life, those formed later have a very much longer half life. This makes a lot of sense because once affinity maturation of the response has occurred during the first few weeks after infection/vaccination, it is more economical to have long lived ASCs.
32. KENT SJ, ZHAO A, BEST SJ, CHANDLER JD, BOYLE DB, RAMSHAW IR: Enhanced T cell immunogenicity and protective efficacy of a human immunodeficiency virus type 1 vaccine regimen consisting of consecutive priming with DNA and boosting with recombinant fowlpox virus. J. Virol. (1998) 72:10180-10188.
33. AMARA RR, VILLINGER F, ALTMAN JD et al.: Control of a mucosal challenge and prevention of AIDS by a multiprotein DNA/MVA vaccine. Science (2001) 292:69-74.
34. COHEN J: Merck re-emerges with a bold AIDS vaccine. Science (2001) 292:24-25.
35. SULLIVAN NJ, SANCHEZ A, ROLLIN PE, YANG Z-Y, NABEL GJ: Development of a preventive vaccine for Ebola virus infection in primates. Nature (2000) 408:605-609.
36. BAROUCH DH, SANTRA S, SCHMITZ JA et al.: Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination. Science (2000) 290:486-492.
37. MUSEY L, HUY, ECKERT L, CHRISTENSEN M, KARCHMER T, MCELRATH MJ: HIV-1 induces cytotoxic T lymphocytes in the cervix of infected woman. J. Exp. Med (1997) 185:293-303. An interesting finding showing how infection by HIV following sexual intercourse leads to the localisation of virus-specific cytotoxic T lymphocytes adjacent to the site where infection was initiated, and where further exposure to the virus may occur.
38. MILLER CJ, MCGHEER JR, GARDNER MB: Mucosal immunity, HIV transmission and AIDS. Lab. Invest. (1992) 68:129-145.
39. RAMSAY AJ: Genetic approaches to the study of cytokine regulation of mucosal immunity. Immunol. Cell Biol. (1995) 73:484-488.
40. FYAN EF, WEBSTER RG, FULLER DH, HAYNES JR, SAN TORO JC, ROBINSON HL: DNA vaccines: protective immunizations by parental, mucosal, and gene-inoculations. Proc. Nat. Acad. Sci. USA (1993) 90:11278-11482.
41. EO SK, GIERYNSKA M, KAMAR AA, ROUSE BT: Prime-boost immunization with DNA vaccine: mucosal route of administration changes the rules. J. Immunol. (2001) 166:5473-5479.
42. KLINMAN DM, TAKENO M, ICHINO M et al.: DNA vaccines: safety and efficacy issues. Springer Semin. Immunopathol. (1997) 19:245-256.
43. ADA G, ISAACS D: Carbohydrate: protein conjugate vaccines. Clin. Microbiol. Infect. (2002): (in press).
44. MOR G, YAMSHCHIKOV G, SEDEGAH M et al.: Induction of neonatal tolerance after administration of a plasmid DNA vaccine. J. Clin. Invest. (1996) 98:2700-2705.
45. ICHINO M, MOR G, CONOVER J et al.: Factors associated with the development of neonatal tolerance after the administration of a plasmid DNA vaccine. J. Immunol. (1999) 162:3814-3818.
46. REICHERT JM, PAPUETTE C: Therapeutic cancer vaccines on trial. Nat. Biotech. (2002) 20:659-663.
47. ROOK GAW, STANFORD JL: Give us this day our daily germs. Immunol. Today (1998) 19:113-116.
48. ROWE J, MACAUBAS C, MONGER T et al.: Heterogeneity in DTaP vaccine-specific cellular immunity during infancy: relationship to variations in the kinetics of postnatal maturation of systemic Th-1 function. J. Infect Dis. (2001)184:80-88.
49. RIEDLER J, BRAUN-FAHRLANDER C, EDER M et al.: Exposure to farming environment during the first year of life protects against the development of asthma and allergy. Lancet (2001) 358:1129-1133. A remarkable retrospective study showing the influence which early exposure to a farming environment has on very young children in greatly reducing the incidence of asthma and other allergies in their later life.
50. LAUENER RP, BIRCHLER T, ADAMSKI J et al.: Expression of CD14 and Toll-like receptor 2 in farmers' and non-farmers' children. Lancet (2002) 360:465-466.
51. WOHLLEBEN G, ERB KJ: Atopic disorders: a vaccine around the corner? Trends Immunol. (2001) 22:618-626.
52. +T cell approach feasible? Nature Immunol. Rev. (2002) 2:283-291.
53. HO DD, HUANG Y: The HIV-1 vaccine race. Cell (2002) 110:135-138.